This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma

This study has been completed.
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00083889
First received: June 3, 2004
Last updated: January 19, 2010
Last verified: January 2010
  Purpose
The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).

Condition Intervention Phase
Carcinoma, Renal Cell Drug: Interferon-alfa Drug: SU011248 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Progression-Free Survival (PFS), Core Radiology Assessment [ Time Frame: Day 28 of each 6-week cycle: duration of treatment phase ]
  • Progression-Free Survival (PFS), Investigator's Assessment [ Time Frame: Day 28 of each 6-week cycle: duration of treatment phase ]

Secondary Outcome Measures:
  • Objective Response, Core Radiology Assessment [ Time Frame: Day 28 of each 6-week cycle: duration of treatment phase ]
  • Objective Response, Investigator's Assessment [ Time Frame: Day 28 of each 6-week cycle: duration of treatment phase ]
  • Overall Survival (OS) [ Time Frame: Clinic visit or telephone contact every 2 months until death ]
  • Time to Tumor Progression (TTP), Core Radiology Assessment [ Time Frame: Randomization to first documentation of tumor progression: duration of treatment phase ]
  • Time to Tumor Progression (TTP), Investigator's Assessment [ Time Frame: Randomization to first documentation of tumor progression: duration of treatment phase ]
  • Duration of Response (DR), Core Radiology Assessement [ Time Frame: Day 28 of each cycle: duraton of treatment phase ]
  • Duration of Response (DR), Investigator's Assessment [ Time Frame: Day 28 of each cycle: duration of treatment phase ]
  • FACT-Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) Subscale [ Time Frame: Day 1 & 28 of each cycle: duration of treatment phase ]
  • FACT-Kidney Symptom Index (FKSI) Subscale [ Time Frame: Day 1 & 28 of each cycle: duration of treatment phase ]
  • Functional Assessment of Cancer Therapy-General (FACT-G) [ Time Frame: Day 1 & 28 of each cycle: duration of treatment phase ]
  • Functional Assessment of Cancer Therapy-General (FACT-G): Physical Well Being (PWB) Subscale [ Time Frame: Day 1 & 28 of each cycle: duration of treatment phase ]
  • Functional Assessment of Cancer Therapy-General (FACT-G): Social/Family Well Being (SWB) Subscale [ Time Frame: Day 1 & 28 of each cycle: duration of treatment phase ]
  • Functional Assessment of Cancer Therapy-General (FACT-G): Emotional Well Being (EWB) Subscale [ Time Frame: Day 1 & 28 of each cycle: duration of treatment phase ]
  • Functional Assessment of Cancer Therapy-General (FACT-G): Functional Well Being (FWB) Subscale [ Time Frame: Day 1 & 28 of each cycle: duration of treatment phase ]
  • EuroQoL Five Dimension (EQ-5D) Health State Index [ Time Frame: Day 1 & 28 of each cycle: duration of treatment phase ]
  • Euro-QoL Visual Analog Scale (EQ-VAS) [ Time Frame: Day 1 & 28 of each cycle: duration of treatment phase ]
  • Plasma Concentrations of Soluble Proteins: Plasma VEGF-A, Plasma VEGF-C, Plasma sVEGFR-3, PLASMA IL-8, and PLASMA bFGF That May be Associated With Tumor Proliferation or Angiogenesis [ Time Frame: Day 1 & Day 28, Cycle 1 to Cycle 4 ]
  • Plasma Concentrations of Soluble Proteins: Plasma Basic Fibroblast Growth Factor (bFGF) That May be Associated With Tumor Proliferation or Angiogenesis [ Time Frame: Day 1 & Day 28, Cycle 1 to Cycle 4 ]
  • Incremental Cost Effectiveness Ratio (ICER) [ Time Frame: post study measurement ]
  • Ctrough Concentrations of SU011248 [ Time Frame: Day 28 of Cycle 1 to Cycle 4 ]
  • Ctrough Concentrations of Metabolite SU012662 [ Time Frame: Day 28 of Cycle 1 to Cycle 4 ]
  • Ctrough Concentrations of SU011248 and Active Metabolite SU012662 [ Time Frame: Day 28 of Cycle 1 to Cycle 4 ]

Enrollment: 750
Study Start Date: August 2004
Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 2 Drug: Interferon-alfa
3 MIU first week, 6 MIU second week, and 9 MIU thereafter three times a week (non-consecutive days) until progression or unacceptable toxicity
Other Name: Roferon
Experimental: 1 Drug: SU011248
50 mg orally daily for 4 weeks and 2 weeks off treatment until progression or unacceptable toxicity
Other Name: Sunitinib, SUTENT

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed renal cell carcinoma of clear cell histology with metastases
  • Evidence of measurable disease by radiographic technique
  • Eastern Cooperative Oncology Group [ECOG] performance status of 0 or 1

Exclusion Criteria:

  • Prior systemic (including adjuvant or neoadjuvant) therapy of any kind for RCC
  • History of or known brain metastases
  • Serious acute or chronic illness or recent history of significant cardiac abnormality
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00083889

  Show 124 Study Locations
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer Inc
ClinicalTrials.gov Identifier: NCT00083889     History of Changes
Obsolete Identifiers: NCT00098657
Other Study ID Numbers: A6181034
Study First Received: June 3, 2004
Results First Received: September 16, 2009
Last Updated: January 19, 2010

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Sunitinib
Interferons
Interferon-alpha
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors

ClinicalTrials.gov processed this record on August 23, 2017